BioGX has reported that its portfolio of Covid-19 tests that work on the nucleocapsid (N-gene) and envelope (E-gene) can identify the Omicron variant of the SARS-CoV-2 virus. The company’s Covid-19 surveillance programme comprises complete in-silico assessment and investigational testing by researchers using sequences of ribonucleic acid (RNA) that bears viral mutations. BioGXn noted that its SARS-CoV-2 portfolio demonstrated the ability to identify all variants of interest and variants of concern, including the Omicron variant, in an analysis.
Sorrento Therapeutics has received orders from its logistics partner to commercially launch its COVISTIX COVID-19 Virus Rapid Antigen Detection Test in Brazil. Apart from this initial loading order, a large diagnostic lab in Brazil placed orders for the tests with Sorrento’s local distribution partner. The tests will be supplied in batches beginning later this month and will carry on until in-country supplies are in line with the rising demand. Furthermore, the company began extending services to other Latin American nations that accept imported Brazil-approved tests.
Chembio Diagnostics has filed an application with the US Food and Drug Administration (FDA) seeking De Novo/510(k) approval for its DPP SARS-CoV-2 Antigen test system. The system can potentially identify SARS-CoV-2 antigens in nearly 20 minutes from a minimally invasive nasal swab sample. The test results can be read using a DPP Micro Reader or DPP Micro Reader 2 optical analyzer. Earlier, the US Biomedical Advanced Research and Development Authority (BARDA) had granted an award to Chembio for developing a point-of-care SARS-CoV-2 antigen test system that leverages the company’s Dual Path Platform (DPP) technology.